Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2010

View Archived Issues

Pharming provides business update

D-156844 beneficial in mouse model of spinal muscular atrophy

Pharmacokinetics of HCV protease inhibitor ABT-450 assessed with and without ritonavir

Durable viral suppression seen with MK-7009 combination therapy in patients with hepatitis C

Targacept receives upfront payment from AstraZeneca

Vion files SPA with FDA for phase II/III trial of Onrigin in AML

FDA advisory committee recommends approval of Actelion's sNDA for Zavesca

Inverness offers to acquire up to 75.79% of Standard Diagnostics' issued shares

BioCryst signs agreements with Merck Serono and Hikma for antiviral peramivir

Sangamo initiates phase IIb trial of SB-509 in DN and phase I trial of CTL product in GM

Pfizer initiates phase II trial of SBI-087 in rheumatoid arthritis

Phase III Revlimid trial meets primary endpoint

Sumitomo describes HSc-025, effects in systemic sclerosis models

Protox Therapeutics presents phase IIb trial results on PRX-302 in BPH

Phase III studies show comparable efficacy with albinterferon alfa-2b vs. peginterferon alfa-2a

Antimitotic tubulin polymerization inhibitors disclosed by CNRS

Rockefeller University, SuperGen claim novel bacterial 2-epimerase inhibitors

Amira describes prostaglandin D receptor antagonists for respiratory disorders

Novel series of glucokinase activators presented by Takeda

Novel series of leukotriene synthesis inhibitors claimed by Biolipox

Nektar Therapeutics reports topline results from phase II trial of NKTR-102 in ovarian cancer

Vivus reported additional results from phase III REVIVE TA-301 study of avanafil for ED

ViroPharma and Sanquin sign agreement for hereditary angioedema drug Cinryze

Inovio and University of Pennsylvania expand license agreement for DNA vaccines

MAP not required to conduct second pivotal efficacy study for Levadex NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...